BeOne Medicines (49BA) Stock Statistics & Valuation Metrics
Total Valuation
BeOne Medicines has a market cap or net worth of EUR 41.00B. The enterprise value is EUR 39.14B.
- Market Cap
- EUR 41.00B
- Enterprise Value
- EUR 39.14B
Share Statistics
BeOne Medicines has 109,786,920 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 109,786,920
- Owned by Insiders
- 64.42%
- Owned by Institutions
- 14.50%
Financial Efficiency
BeOne Medicines’s return on equity (ROE) is 0.07 and return on invested capital (ROIC) is 4.74%.
- Return on Equity (ROE)
- 0.07
- Return on Assets (ROA)
- 0.04
- Return on Invested Capital (ROIC)
- 4.74%
- Return on Capital Employed (ROCE)
- 0.07
- Revenue Per Employee
- 445.25K
- Profits Per Employee
- 23.91K
- Employee Count
- 12,000
- Asset Turnover
- 0.65
- Inventory Turnover
- 1.10
Valuation Ratios
The current PE Ratio of BeOne Medicines is 68.05. BeOne Medicines’s PEG ratio is -0.75.
- PE Ratio
- 68.05
- PS Ratio
- 6.73
- PB Ratio
- 10.84
- Price to FCF
- 31.07
- Price to Operating Cash Flow
- 39.47
- PEG Ratio
- -0.75
Income Statement
In the last 12 months, BeOne Medicines had revenue of 5.34B and earned 286.93M in profits. Earnings per share was 33.80.
- Revenue
- 5.34B
- Gross Profit
- 4.67B
- Operating Income
- 447.14M
- Pretax Income
- 416.85M
- Net Income
- 286.93M
- EBITDA
- 616.77M
- Earnings Per Share (EPS)
- 33.80
Cash Flow
In the last 12 months, operating cash flow was 1.79B and capital expenditures -430.42M, giving a free cash flow of 1.36B billion.
- Operating Cash Flow
- 1.79B
- Free Cash Flow
- 1.36B
- Free Cash Flow per Share
- 12.64
Dividends & Yields
BeOne Medicines pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 3.22%
- Earnings Yield
- 1.45%
Stock Price Statistics
- Beta
- 0.80
- 52-Week Price Change
- 23.57%
- 50-Day Moving Average
- 315.76
- 200-Day Moving Average
- 278.15
- Relative Strength Index (RSI)
- 62.41
- Average Volume (3m)
- 14
Important Dates
BeOne Medicines upcoming earnings date is Mar 31, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 31, 2027
- Ex-Dividend Date
- ―
Financial Position
BeOne Medicines as a current ratio of 3.41, with Debt / Equity ratio of 45.85%
- Current Ratio
- 3.41
- Quick Ratio
- 3.08
- Debt to Market Cap
- 0.06
- Net Debt to EBITDA
- -4.13
- Interest Coverage Ratio
- 7.68
Taxes
In the past 12 months, BeOne Medicines has paid 129.92M in taxes.
- Income Tax
- 129.92M
- Effective Tax Rate
- 0.31
Enterprise Valuation
BeOne Medicines EV to EBITDA ratio is 27.61, with an EV/FCF ratio of 27.87.
- EV to Sales
- 6.03
- EV to EBITDA
- 27.61
- EV to Free Cash Flow
- 27.87
- EV to Operating Cash Flow
- 25.04
Balance Sheet
BeOne Medicines has EUR 5.78B in cash and marketable securities with EUR 1.15B in debt, giving a net cash position of EUR 4.63B billion.
- Cash & Marketable Securities
- EUR 5.78B
- Total Debt
- EUR 1.15B
- Net Cash
- EUR 4.63B
- Net Cash Per Share
- EUR 42.19
- Tangible Book Value Per Share
- EUR 50.86
Margins
Gross margin is 88.39%, with operating margin of 17.82%, and net profit margin of 13.83%.
- Gross Margin
- 88.39%
- Operating Margin
- 17.82%
- Pretax Margin
- 17.10%
- Net Profit Margin
- 13.83%
- EBITDA Margin
- 21.85%
- EBIT Margin
- 19.15%
Analyst Forecast
The average price target for BeOne Medicines is EUR 409.56, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 409.56
- Price Target Upside
- 18.37% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 12
- Revenue Growth Forecast
- 26.78%
- EPS Growth Forecast
- 1621.41%
Scores
- Smart Score
- 10
- AI Score
- ―
